type 2 diabetes – Medxy AI

Gender Differences in Hypoglycaemia Among Type 1 and Insulin-Treated Type 2 Diabetes: Insights from the Hypo-METRICS Study

By MedXY 06/24/2026

This study evaluates gender-based differences in hypoglycaemia symptoms and frequency among people with type 1 and insulin-treated type 2 diabetes using continuous glucose monitoring in real-world settings.

Diabetes & Endocrinology news

Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data

By MedXY 06/20/2026

A retrospective cohort study evaluating 1-year weight loss, glycaemic control, and safety outcomes among adults with obesity and type 2 diabetes treated with semaglutide, tirzepatide, or sleeve gastrectomy, highlighting higher efficacy with surgery but varying safety profiles.

Diabetes & Endocrinology news Public Health

Publicly Funded Intermittently Scanned Continuous Glucose Monitoring Is Linked to Fewer Hospitalizations in Insulin-Treated Type 2 Diabetes

By MedXY 06/17/2026

A large real-world study found that public implementation of intermittently scanned continuous glucose monitoring in insulin-treated type 2 diabetes was linked to better HbA1c, fewer acute diabetes hospitalizations, shorter stays, and lower inpatient costs.

Cardiology Diabetes & Endocrinology news

Tirzepatide vs Dulaglutide: New Post Hoc SURPASS-CVOT Data Point to Broader Cardiorenal Benefit

By MedXY 06/17/2026

Post hoc SURPASS-CVOT analysis found tirzepatide lowered a broad 6-component cardiorenal composite versus dulaglutide in high-risk patients with type 2 diabetes, with more gastrointestinal adverse events but similar overall safety.

Diabetes & Endocrinology news Pathology & Lab Medicine/Bệnh học

A Three-miRNA Plasma Signature May Help Detect Early Beta Cell Dysfunction Before Overt Type 2 Diabetes Progression

By MedXY 06/10/2026

Plasma profiling identified a three-miRNA panel associated with beta cell rate sensitivity across glucose tolerance stages, suggesting a minimally invasive approach to detect early insulin secretory decline.

Cardiology Diabetes & Endocrinology news

Individual GLP-1 Receptor Agonists and SGLT2 Inhibitors Show Largely Comparable Cardiovascular Protection in Type 2 Diabetes

By MedXY 06/10/2026

A multinational real-world study found broadly similar cardiovascular effectiveness across individual GLP-1 receptor agonists and SGLT2 inhibitors in metformin-treated type 2 diabetes, including among patients with established cardiovascular disease.

Diabetes & Endocrinology news Ophthalmology

Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study

By MedXY 06/10/2026

In a large OHDSI network study of adults with type 2 diabetes, semaglutide was not associated with a higher or lower risk of neovascular age-related macular degeneration.

Cardiology Diabetes & Endocrinology news

Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Based 5- and 10-Year Follow-Up After Two Clinical Trials

By MedXY 06/10/2026

Long-term follow-up after two lifestyle trials found that reductions in visceral fat, more than overall weight loss, were linked to sustained cardiometabolic benefits and a lower risk of type 2 diabetes.

Diabetes & Endocrinology news

Cagrilintide-Semaglutide (CagriSema) Lowers HbA1c Better Than Semaglutide Alone in Type 2 Diabetes

By MedXY 06/10/2026

REIMAGINE 2 found that once-weekly cagrilintide-semaglutide lowered HbA1c more than semaglutide alone in adults with type 2 diabetes and overweight or obesity, with a safety profile consistent with known gastrointestinal effects.

Cardiology Diabetes & Endocrinology news

Precision Prescribing of SGLT2 Inhibitors in Type 2 Diabetes for Primary Prevention of Heart Failure

By MedXY 06/10/2026

A validation study developed SABRE, a model that estimates how much SGLT2 inhibitors can reduce heart failure risk in people with type 2 diabetes, helping clinicians target preventive treatment more precisely.

Cardiology Diabetes & Endocrinology news

Precision Prescribing of SGLT2 Inhibitors in People With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study

By MedXY 06/10/2026

The SABRE model estimates which people with type 2 diabetes may benefit most from SGLT2 inhibitors to prevent heart failure before it develops.

Diabetes & Endocrinology news Public Health

Early 15% Weight Loss After Type 2 Diabetes Diagnosis Linked to Lower Complication Risk

By MedXY 06/09/2026

In a large U.K. cohort, losing at least 15% of body weight within 2 years of type 2 diabetes diagnosis was linked to lower risks of heart, kidney, and eye complications, along with better glucose and blood pressure control.

Clinical Updates news

CagriSema for Early Type 2 Diabetes: Interpreting the Phase 3a REIMAGINE 1 Trial in the Context of Incretin–Amylin Combination Therapy

By MedXY 06/09/2026

REIMAGINE 1 shows that once-weekly CagriSema significantly reduced HbA1c and bodyweight versus placebo in early type 2 diabetes, with mainly gastrointestinal adverse events and a mechanistically compelling incretin–amylin profile.

Cardiology Nephrology news

Finerenone Shows Consistent Cardiovascular and Kidney Benefit Across CKM Syndrome Stages in Type 2 Diabetes and CKD

By MedXY 06/07/2026

A post hoc FIDELITY analysis suggests finerenone improves cardiovascular and kidney outcomes across CKM stages and may modestly shift patients toward CKM regression over time.

Cardiology Diabetes & Endocrinology news

Diabetes Markedly Raises Sudden Cardiac Death Risk, With the Greatest Excess Hazard in Younger Adults

By MedXY 06/07/2026

A Danish nationwide study found substantially higher sudden cardiac death rates in both type 1 and type 2 diabetes, especially at younger ages, with meaningful loss of life expectancy attributable to sudden cardiac death.

Diabetes & Endocrinology news Oncology

Early HbA1c Control After Type 2 Diabetes Diagnosis May Shape Long-Term Cancer Risk

By MedXY 06/05/2026

In a large Hong Kong cohort with newly diagnosed type 2 diabetes, higher early HbA1c exposure was associated with greater long-term cancer risk, suggesting that glycaemic control soon after diagnosis may matter more than later improvement.

Diabetes & Endocrinology news Public Health

Food Coloring Additives Linked to Higher Type 2 Diabetes Risk in a Large French Cohort

By MedXY 06/05/2026

A large French cohort study found that higher exposure to several food coloring additives was associated with increased incidence of type 2 diabetes, highlighting the need for further research and possible reevaluation of some additives.

Diabetes & Endocrinology news Ophthalmology

No Signal for Increased Neovascular AMD Risk With Semaglutide in Adults With Type 2 Diabetes: Interpretation of a Large OHDSI Network Study

By MedXY 06/04/2026

A multinational OHDSI network analysis found no meaningful association between semaglutide use and neovascular age-related macular degeneration among adults with type 2 diabetes across cohort and self-controlled designs.

Cardiology Diabetes & Endocrinology news

Precision Prescribing of SGLT2 Inhibitors in Type 2 Diabetes for Primary Prevention of Heart Failure

By MedXY 06/03/2026

A validated model, SABRE, estimates who with type 2 diabetes may gain the most heart-failure prevention benefit from SGLT2 inhibitors, enabling more precise, individualized prescribing.

Cardiology Diabetes & Endocrinology news

Visceral Fat Loss, Not Weight Loss Alone, May Be the More Durable Target for Long-Term Cardiometabolic Health

By MedXY 06/03/2026

Long-term follow-up of CENTRAL and DIRECT-PLUS suggests MRI-measured visceral fat loss during lifestyle intervention predicts sustained cardiometabolic benefit and lower future type 2 diabetes risk, even after substantial weight regain.